netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Search
 Formulary Chapter 4: Central nervous system - Full Chapter
Notes:

As psychiatric services are provided by Northumberland, Tyne and Wear NHS Foundation Trust (NTW) the drugs available for Sections 4.1, 4.2, 4.3 and 4.4 are those listed in the Formulary used by NTW which is the North of Tyne Formulary

 Details...
04.09.01  Expand sub section  Dopaminergic drugs used in Parkinsons disease
04.09.01  Expand sub section  Dopamine receptor agonists
04.09.01  Expand sub section  Levodopa
Co-Beneldopa
(benserazide + levodpoa)
View adult BNF View SPC online
Formulary Capsules: 12.5/50, 25/100, 50/200
Dispersible Tablets: 12.5/50, 25/100
CR capsules: 25/100
 
   
Co-Careldopa
(carbidopa + levedopa)
View adult BNF View SPC online
Formulary Tablets: 12.5/50, 10/100, 25/100, 25/250
MR Tablets: 25/100, 50/200
 
   
Co-Careldopa and Entacapone
View adult BNF View SPC online
Formulary
Green +
Stalevo® and Sastravi® and Stanek® brands available in the following strengths
  • 50 mg/12.5 mg/200 mg Tablets: levodopa 50 mg, carbidopa 12.5 mg, entacapone 200 mg
  • 75 mg/18.75 mg/200 mg Tablets: levodopa 75 mg, carbidopa 18.75 mg, entacapone 200 mg
  • 100 mg/25 mg/200 mg Tablets: levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg
  • 125 mg/31.25 mg/200 mg Tablets: levodopa 125 mg, carbidopa 31.25 mg, entacapone 200 mg
  • 150 mg/37.5 mg/200 mg Tablets: levodopa 150 mg, carbidopa 37.5 mg, entacapone 200 mg
  • 175 mg/43.75 mg/200 mg Tablets: levodopa 175 mg, carbidopa 43.75 mg, entacapone 200 mg
  • 200 mg/50 mg/200 mg Tablets: levodopa 200 mg, carbidopa 50 mg, entacapone 200 mg
     
  •    
    04.09.01  Expand sub section  Monoamine-oxidase-B inhibitors
    04.09.01  Expand sub section  Catachol-O-methyltransferase inhibitors to top
    04.09.01  Expand sub section  Amantadine
     ....
     Non Formulary Items
    Levodopa

    View adult BNF View SPC online
    Non Formulary
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

    Amber

    These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

    Green +

    Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

    Green

    These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

    netFormulary